Relypsa raises $80 million for hyperkalaemia drug

Relypsa said on 15 August that it closed an $80 million series C preferred stock financing after it disclosed in a US Securities and Exchange Commission (SEC) filing on 10 August that it raised $49.7 million to begin a Phase III trial this year and a future new drug application (NDA) to the US FDA for patiromer (RLY5016), a high-capacity, non-absorbed oral potassium binder to treat hyperkalaemia in patients with diabetes, chronic kidney disease (CKD) and heart failure (scripintelligence.com, 14 August 2012).

The series C financing included existing investors OrbiMed Advisors, 5AM Ventures, New Leaf Venture Partners, Sprout Group, Delphi Ventures and...